Associate Professor, Comprehensive Cancer Center, Yale University School of Medicine
Oncology
Dr. Harriet M. Kluger, MD
|
|
Give Review
Harriet M. Kluger is an expert in the field of Oncology. She has 1 awards "CMS Meaningful Use Stage 1 Certification". Harriet Kluger is a published doctor and has 85 publications published. The lastest was: 'Systemic Immunotherapy for the Treatment of Brain Metastases.' She accepts Medicare.
Publications
- Genomic characterization of sarcomatoid transformation in clear Cell renal Cell carcinoma.
- Clinical trials in melanoma patients with Brain metastases.
- First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70.
- Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of Brain metastases?
- Clinicopathological and immunohistochemical characteristics of papillary renal Cell carcinoma with emphasis on subtyping.
- Precipitation of AutoImmune Diabetes With Anti-PD-1 Immunotherapy.
- Identification of novel radiosensitizers in a high-throughput, Cell-based screen for DSB repair inhibitors.
- Role of chitinase 3-like-1 and semaphorin 7a in pulmonary Melanoma metastasis.
- Combination Therapy with Anti-CTLA-4 and Anti-PD-1 Leads to Distinct Immunologic Changes In Vivo.
- PAX-8 expression in renal tumours and distant sites: A useful marker of primary and metastatic renal Cell carcinoma?
- Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma.
- Pregabalin for the Treatment of Painful Hand-Foot Skin Reaction Associated With Dabrafenib.
- NY-ESO-1 as a Potential Immunotherapeutic Target in Renal Cell Carcinoma.
- Correlation of somatic mutations and clinical outcome in Melanoma patients treated with carboplatin, paclitaxel, and sorafenib.
- Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205.
- Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) Melanoma.
- Radiation sensitivity and sensitization in Melanoma.
- Nivolumab plus ipilimumab in advanced Melanoma.
- Ipilimumab-induced Perforating Colitis.
- Expression of drug targets in primary and matched metastatic renal Cell carcinoma tumors.
- c-Met is a prognostic marker and potential therapeutic target in clear Cell renal Cell carcinoma.
- Vascularity of primary and metastatic renal Cell carcinoma specimens.
- Studies of NVP-BEZ235 in Melanoma.
- CD70 expression patterns in renal Cell carcinoma.
- Exome sequencing identifies recurrent somatic RAC1 mutations in Melanoma.
- Immunotherapy for metastatic Melanoma.
- Case Report: response to ipilimumab in a patient with HIV with metastatic Melanoma.
- Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell Cancer.
- Molecular alternations in uveal Melanoma.
- Melanoma Brain metastases: is it time to reassess the bias?
- A phase 2 trial of dasatinib in advanced Melanoma.
- Plasma markers for identifying patients with metastatic Melanoma.
- Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating Melanoma.
- Ipilimumab: a promising immunotherapy for Melanoma.
- Benefits of biomarker selection and clinico-pathological covariate inclusion in breast Cancer prognostic models.
- Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in Melanoma tissue microarrays.
- Melanoma prognostic model using tissue microarrays and genetic algorithms.
- Chemotherapy and biologic therapies for Melanoma: do they work?
- C-Raf is associated with disease progression and cell proliferation in a subset of Melanomas.
- Phosphatidylinositol-3-kinase as a therapeutic target in Melanoma.
- Expression of sorafenib targets in Melanoma patients treated with carboplatin, paclitaxel and sorafenib.
- Classification of renal Cell carcinoma based on expression of VEGF and VEGF receptors in both tumor Cells and endothelial Cells.
- Expression of Aurora A (but not Aurora B) is predictive of survival in breast Cancer.
- Suppressor role of activating transcription factor 2 (ATF2) in skin Cancer.
- Assessing expression of apoptotic markers using large cohort tissue microarrays.
- Increased expression of the E3 ubiquitin ligase RNF5 is associated with decreased survival in breast Cancer.
- High HSP90 expression is associated with decreased survival in breast Cancer.
- Rab33A: characterization, expression, and suppression by epigenetic modification.
- Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in Melanoma.
- Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast Cancer.
- Using a xenograft model of human breast Cancer metastasis to find genes associated with clinically aggressive disease.
- Automated quantitative analysis of E-cadherin expression in lymph node metastases is predictive of survival in invasive ductal breast Cancer.
- Automated quantitative Analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma.
- Automated quantitative Analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome.
- Expression profiling reveals novel pathways in the transformation of melanocytes to Melanomas.
- alphaB-crystallin as a marker of lymph node involvement in Breast carcinoma.
- cDNA microarray analysis of invasive and tumorigenic phenotypes in a breast Cancer model.
- Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast Cancer by large cohort tissue microarray analysis.
- Subcellular localization of activating transcription factor 2 in Melanoma specimens predicts patient survival.
- PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases.
- Expression of drug targets in patients treated with sorafenib, Carboplatin and Paclitaxel.
- Incidence of the V600K mutation among Melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.
- Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung Cancer cells.
- In vitro studies of dasatinib, its targets and predictors of sensitivity.
- Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast Cancer.
- HSP90 as a marker of progression in Melanoma.
- Regulation of non-AU-rich element containing c-fms proto-oncogene expression by HuR in breast Cancer.
- Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast Cancer.
- The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic Melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization.
- Her2/neu is not a commonly expressed therapeutic target in Melanoma -- a large cohort tissue microarray study.
- Microvessel area as a predictor of sorafenib response in metastatic renal Cell carcinoma.
- Metastatic myoepithelial Carcinoma of the vulva treated with carboplatin and paclitaxel.
- Characterizing disease States from topological properties of transcriptional regulatory networks.
- Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell Cancer.
- A role for ATF2 in regulating MITF and Melanoma development.
- USP13 enzyme regulates Siah2 ligase stability and activity via noncatalytic ubiquitin-binding domains.
- Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and Malignant melanocytic lesions.
- PKC? Promotes Oncogenic Functions of ATF2 in the Nucleus while Blocking Its Apoptotic Function at Mitochondria.
- Association between pathways in regulatory networks.
- Centrosomal Chk2 in DNA damage responses and Cell cycle progression.
- Apoptosis: a clinical perspective.
- MEK targeting in N-RAS mutated metastatic Melanoma.
- Advances in therapy for melanoma Brain metastases.
- Systemic Immunotherapy for the Treatment of Brain Metastases.
Schools
Tel Aviv University Sackler Faculty of Medicine
University New Mexico
Highland Genl Hospital
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Alameda County Medical Center -
University of New Mexico -
Tel Aviv University Sackler
Hospital
-
Yale-New Haven Hospital
Drug Facts
| NPI NUMBER | 1528042819 | |
| NPPES Provider LastName | KLUGER | |
| NPPES Provider FirstName | HARRIET | |
| NPPES Provider ZIPCode | 065191369 | |
| NPPES Provider State | CT | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 140.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1528042819 |
| Last Name Of The Provider | KLUGER |
| First Name Of The Provider | HARRIET |
| View All |
Similar Doctors
|
|
Dr. Hari A. Deshpande, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tara B. Sanft, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jill Lacy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mario Sznol, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stuart E. Seropian, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Warren D. Shlomchik, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph W. Kim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven D. Gore, MD
This Doctor is OpenDoctor Recommended.
|